| Literature DB >> 35292055 |
Jun Yu1, Lianrui Li1, Jie Liu1, Zhiyong Chen2.
Abstract
BACKGROUND: To investigate the efficacy of Qingre Lishi Decoction(QLRD), in the treatment of acute gouty arthritis, and its influence on the expression levels of inflammatory factor nucleotide-binding oligomerization domain-like receptor(NALP 3) in patients.Entities:
Keywords: Acute gouty arthritis; Inflammatory factor; NALP3; Serum uric acid; “Heat-clearing and diuresis-promoting” prescription
Mesh:
Substances:
Year: 2022 PMID: 35292055 PMCID: PMC8922783 DOI: 10.1186/s13018-022-03046-z
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Changes of scores for traditional Chinese medicine symptoms in both groups before/after treatment (points, ± s)
| Group | Joint redness, swelling, heat and pain | Joint flexion and extension disorders | Scanty dark urine | Constipation | ||||
|---|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| Observation group (n = 39) | 4.18 ± 0.92 | 1.19 ± 0.26a | 2.75 ± 0.60 | 0.76 ± 0.17a | 2.66 ± 0.59 | 0.68 ± 0.17a | 2.42 ± 0.48 | 0.57 ± 0.17a |
| Control group (n = 39) | 4.05 ± 0.88 | 1.84 ± 0.30a | 2.77 ± 0.53 | 1.34 ± 0.28a | 2.72 ± 0.56 | 1.04 ± 0.20a | 2.46 ± 0.44 | 1.15 ± 0.33a |
| 0.638 | 10.225 | 0.156 | 11.058 | 0.461 | 8.565 | 0.384 | 9.757 | |
| P | 0.526 | 0.000 | 0.876 | 0.000 | 0.646 | 0.000 | 0.702 | 0.000 |
Compared with before treatment, aP < 0.05
Comparison of clinical efficacy between two groups of patients [n, (%)]
| Group | n | Excellent | Valid | Invalid | Total effective rate |
|---|---|---|---|---|---|
| Observation group | 39 | 19 (48.72) | 18 (46.14) | 2 (5.13) | 37 (94.87) |
| Control group | 39 | 16 (41.03) | 14 (35.90) | 9 (23.08) | 30 (76.92) |
| 13.297 | |||||
| 0.000 |
Compared with before treatment, aP < 0.05
Fig. 1Comparison of clinical efficacy between two groups of patients
Changes of laboratory indexes in both groups before/after treatment (points, ± s)
| Group | UA (μmol/L) | ESR (mm/h) | IL-1β (ng/L) | NALP3 (ng/L) | ||||
|---|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| Observation group (n = 39) | 505.06 ± 54.97 | 339.20 ± 38.22a | 45.88 ± 8.54 | 16.63 ± 4.85a | 52.33 ± 9.25 | 32.94 ± 7.69a | 9.46 ± 1.79a | 7.08 ± 1.47a |
| Control group (n = 39) | 515.18 ± 50.13 | 386.48 ± 40.69a | 45.92 ± 8.61 | 22.78 ± 5.10a | 53.50 ± 8.12 | 41.57 ± 8.83a | 9.86 ± 2.14a | 8.17 ± 1.77a |
| 0.850 | 5.289 | 0.021 | 5.457 | 0.594 | 4.603 | 0.895 | 2.959 | |
| P | 0.398 | 0.000 | 0.984 | 0.000 | 0.555 | 0.000 | 0.373 | 0.004 |
Compared with before treatment, aP < 0.05
Fig. 2Changes of laboratory indexes in both groups before/after treatment